Travere Therapeutics, Inc. (TVTX) fair value analysis
Nasdaq · Updated 2026-10-19
TVTX price how computed
Valuation status
Awaiting full valuationTVTX does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards.
We require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $49.60
- Sector
- Healthcare
- 12-month range
- $26.79–$67.52
- Market cap
- $4.61B
- From 52-week high
- -26.5%
- Shares outstanding
- 93M
- Rank in Healthcare by quality score
- #72 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and commercializing medicines for rare kidney diseases and other serious conditions. The company operates primarily in the United States and serves patients globally through its research, development, and commercial operations.
TVTX currently ranks #72 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $4.61B
- P/E (trailing)
- 78x
- Revenue (TTM)
- $591M
- Net margin
- -7.4%
- EPS (TTM)
- $0.64
- Gross margin
- 98.7%
- Debt / equity
- 25.16
- Revenue growth (3-yr avg)
- 119.1%
- Shares outstanding
- 93M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 21 · oversold
- 50-day average
- $61.37
- 200-day average
- $45.82
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-10-29
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▼ miss (-164.3%)
2026-03 ▲ beat (+183.3%)
2025-12 ▲ beat (+1025.0%)
2025-09 ▲ beat (+837.5%)
2025-06 ▲ beat (+225.0%)
2025-03 ▲ beat (+51.3%)
2024-12 ▼ miss (-24.1%)
2024-09 ▲ beat (+14.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 14 buy · 1 hold · 0 sell (15 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $75.2
- Target vs last price
- +51.6%
What our data shows for TVTX
- Our model validated 3 trailing price-to-earnings windows for TVTX, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $26.79–$67.52.
- The 14-day relative strength index sits at an oversold 21.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- TVTX's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent TVTX news
TickrTrends' derived news-sentiment signal for TVTX is currently leaning positive, computed from recent coverage.
- Travere Therapeutics (TVTX) to Present New FILSPARI Data at ASN Kidney Week 2026 (gurufocus.com, 2026-10-02)
- TVTX Looks 57.0% Overvalued on GF Value™ (gurufocus.com, 2026-09-23)
- TVTX Looks 64.1% Overvalued on GF Value™ (gurufocus.com, 2026-09-22)
What people are saying
Follow the TVTX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for TVTX show a decline in quality grade from A to B this week, while the stock's RSI zone has shifted from neutral to oversold. The current valuation verdict remains awaiting full valuation as additional analysis is completed.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TVTX's trend state shifted this week from an uptrend to mixed conditions, as indicated by the 50/200-day moving average relationship. The stock remains under valuation review with a verdict of awaiting full valuation. This transition to mixed momentum reflects changing technical positioning in the Healthcare sector name.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is TVTX stock undervalued?
TVTX does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is TVTX's TickrTrends verdict?
TVTX is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does TVTX compare to other Healthcare stocks?
TVTX ranks #72 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is TVTX overbought or oversold?
TVTX's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does TVTX report earnings next?
TVTX's next earnings report is scheduled for 2026-10-29, per the published earnings calendar.
Does TVTX usually beat earnings estimates?
Over its last 8 reported quarters TVTX beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about TVTX?
Of 15 analysts covering TVTX, 14 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $75.2 (+51.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.